Journal
INFECTION AND DRUG RESISTANCE
Volume 13, Issue -, Pages 3295-3300Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IDR.S272645
Keywords
COVID-19; UC-MSCs; critically ill; cell transplantation; case report
Categories
Funding
- National Key Research and Development Program of China [2016YFA0101000, 2016YFA0101003, 2018YFA0109800, 2020YFC0844000]
- CAMS Innovation Fund for Medical Sciences [2017-I2M -3-007]
- 111 Project [B18007]
Ask authors/readers for more resources
Background: COVID-19 (coronavirus disease 2019) has become a global public health emergency since patients were first detected in Wuhan, China, in December 2019. Currently, there are no satisfying antiviral medications and vaccines available. Case Presentation: We reported the treatment process and clinical outcome of a 48-year-old man critically ill COVID-19 patient who received transfusion of allogenic human umbilical cord mesenchymal stem cells (UC-MSCs). Conclusions: We proposed that UC-MSC transfusion might be a new option for critically ill COVID-19. Although only one case we were shown, more similar clinical cases are inquired for further evidence providing the potential effectiveness of UC-MSC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
